Efficacy and safety of Aethoxysklerol® (polidocanol) 0.5%, 1% and 3% in comparison with placebo solution for the treatment of varicose veins of the lower extremities in Chinese patients (ESA-China Study)

Phlebology

Volumn 27, Issue 4, 2012, Pages 184-190

  Zhang, J ^a   Jing, Z ^b   Schliephake, D E ^c   Otto, J ^c   Malouf, G M ^d   Gu, Y Q ^e  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c Chemische Fabrik Kreussler and Co GmbH   (Germany)

^d WESTMEAD HOSPITAL   (Australia)

^e CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

C1 C2 varicose veins; Chinese population; Polidocanol; Sclerotherapy

Indexed keywords

POLIDOCANOL;

ADULT; AGED; ARTICLE; CHINESE; COMPRESSION GARMENT; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; FEMALE; HUMAN; HYPERPIGMENTATION; INJECTION SITE DISCOLORATION; INJECTION SITE PAIN; LEG VARICOSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE HEMATOMA; PRIORITY JOURNAL; PROSPECTIVE PAYMENT; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SCLEROTHERAPY; SIDE EFFECT; SPIDER VEIN; TREATMENT RESPONSE; VEIN OCCLUSION; VENOUS REFLUX;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LOWER EXTREMITY; MALE; MIDDLE AGED; PATIENT SAFETY; PATIENT SATISFACTION; PLACEBOS; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; QUESTIONNAIRES; SAPHENOUS VEIN; SCLEROSING SOLUTIONS; SCLEROTHERAPY; TIME FACTORS; TREATMENT OUTCOME; ULTRASONOGRAPHY, DOPPLER, DUPLEX; VARICOSE VEINS;

EID: 84861004441     PISSN: 02683555     EISSN: 14333031     Source Type: Journal    
DOI: 10.1258/phleb.2011.010094     Document Type: Article

References (14)

1. Rabe E, Pannier-Fischer F, Bromen K, et al. Bonner Venenstudie der Deutschen Gesellschaft fur Phlebologie. Phlebologie 2003;32:1-14
2. McLafferty RB, Passman MA, Caprini JA, et al. Increasing awareness about venous disease: the American Venous Forum expands the National Venous Screening Program. J Vasc Surg 2008;48:394-9
3. Evans CJ, Fowkes FG, Ruckley CV, Lee AJ. Prevalence of varicose veins and chronic venous insufficiency in men and women in the general population: Edinburgh Vein Study. J Epidemiol Commun Health 1999; 53:149-53
4. Sun JM. Epidemiologic study on peripheral vascular diseases in Shanghai. Chin J Surg 1990;28:480-3
5. Ting ACW, Cheng SWK, Wu LLH, Cheung GCY. Anatomical distribution of chronic venous insufficiency in a Chinese population. Phlebology 1999;14: 29-32
6. Eklof B, Rutherford RB, Bergan JJ, et al. Revision of the CEAP classification for chronic venous disorders: consensus statement. J Vasc Surg 2004;40:1248-52
7. Rabe E, Schliephake D, Otto J, Breu FX, Pannier F. Sclerotherapy of telangiectases and reticular veins: a double-blind, randomized, comparative clinical trial of Polidocanol, sodium tetradecyl sulphate and isotonic saline (EASI study). Phlebology 2010;25:124-31
8. Satokawa H, Hoshino S, Sakaguchi S, et al. Evaluation of concentrations of Polidocanol for sclerotherapy in the treatment of varicose veins. Jpn J Phlebol 2004;15: 33-44
9. Yamaki T, Nozaki M, Iwasaka S. Comparative study of duplex-guided foam sclerotherapy and duplexguided liquid sclerotherapy for the treatment of superficial venous insufficiency. Dermatol Surg 2004;30: 718-22
10. Miyazaki K, Nishibe T, Sata F, et al. Long-term results of treatments for varicose veins due to greater saphenous vein insufficiency. Internat Angiol 2005;24:282-6
11. Goldman MP, Pfeifer JR, Villavicencio JL. Double-blind, prospective, randomized, comparative multicenter trial between Aethoxysklerol (Polidocanol) and Sotradecol in the management of varicose veins of the lower extremities. Abstract Book Union International Phlebology 1998;29:29
12. Goldman MP. Treatment of varicose and telangiectatic leg veins: double-blind prospective comparative trial between Aethoxysklerol and Sotradecol. Dermatol Surg 2002;28:152-5
13. Summary of Product Information. Aethoxysklerol Germany 0.25-3%. October 2009
14. Guex JJ, Schliephake DE, Otto J, Mako S, Allaert FA. The French Polidocanol study on long-term side effects: a survey covering 3,357 patient years. Dermatol Surg 2010;36(Suppl 2):993-1003